Disease-free interval after primary treatment predicts prognosis of recurrent endometrial carcinoma.
Ueda
Yutaka
Y
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Matsumura
Yuki
Y
Egawa-Takata
Tomomi
T
Miyake
Takahito
T
Miyatake
Takashi
T
Yoshino
Kiyoshi
K
Fujita
Masami
M
Matsuzaki
Shinya
S
Yokoyama
Takuhei
T
Miyoshi
Yukari
Y
Yamasaki
Masato
M
Enomoto
Takayuki
T
Kimura
Tadashi
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate